NASDAQ:KLRS Kalaris Therapeutics (KLRS) Stock Price, News & Analysis $1.28 -0.07 (-5.19%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$1.29 +0.01 (+0.78%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Kalaris Therapeutics Stock (NASDAQ:KLRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kalaris Therapeutics alerts:Sign Up Key Stats Today's Range$1.25▼$1.3750-Day Range$1.28▼$3.3052-Week Range$1.25▼$11.88Volume37,986 shsAverage Volume84,329 shsMarket Capitalization$30.47 millionP/E RatioN/ADividend YieldN/APrice Target$18.75Consensus RatingModerate Buy Company Overview Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.AI Generated. May Contain Errors. Read More Kalaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreKLRS MarketRank™: 1.870533837745 of 5 starsKalaris Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 647th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingKalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialKalaris Therapeutics has a consensus price target of $18.75, representing about 1,364.8% upside from its current price of $1.28.Amount of Analyst CoverageKalaris Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Kalaris Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kalaris Therapeutics are expected to decrease in the coming year, from ($1.92) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kalaris Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kalaris Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalaris Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.83% of the float of Kalaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverKalaris Therapeutics has a short interest ratio ("days to cover") of 5.43.Change versus previous monthShort interest in Kalaris Therapeutics has recently increased by 19.66%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKalaris Therapeutics does not currently pay a dividend.Dividend GrowthKalaris Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Kalaris Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kalaris Therapeutics' insider trading history. Receive KLRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLRS Stock News HeadlinesKalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Consensus Target Price of $18.75 According to BrokeragesNovember 17, 2026 | americanbankingnews.comKalaris Therapeutics (NASDAQ:KLRS) Stock Rating Raised to Hold at Wall Street ZenNovember 16, 2026 | americanbankingnews.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 22 at 1:00 AM | Paradigm Press (Ad)Kalaris Therapeutics IncNovember 12, 2026 | markets.ft.comKalaris Therapeutics Reports Q3 Net LossNovember 10, 2026 | rttnews.comKalaris Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 10, 2026 | globenewswire.comKalaris Therapeutics Inc (KLRS)October 3, 2026 | investing.comKalaris to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comSee More Headlines KLRS Stock Analysis - Frequently Asked Questions How have KLRS shares performed this year? Kalaris Therapeutics' stock was trading at $8.44 at the beginning of the year. Since then, KLRS shares have decreased by 84.8% and is now trading at $1.28. How were Kalaris Therapeutics' earnings last quarter? Kalaris Therapeutics Inc. (NASDAQ:KLRS) released its earnings results on Tuesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.06. Who are Kalaris Therapeutics' major shareholders? Top institutional investors of Kalaris Therapeutics include Goldman Sachs Group Inc. (0.17%), Empowered Funds LLC (0.09%) and Independent Advisor Alliance (0.05%). View institutional ownership trends. How do I buy shares of Kalaris Therapeutics? Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/10/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KLRS's financial health is in the Red zone, according to TradeSmith. KLRS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KLRS CIK1754068 Webwww.kalaristx.com Phone(650) 249-2727FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Kalaris Therapeutics$18.75 High Price Target$25.00 Low Price Target$14.00 Potential Upside/Downside+1,364.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.76% Return on Assets-41.32% Debt Debt-to-Equity RatioN/A Current Ratio10.00 Quick Ratio10.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book0.64Miscellaneous Outstanding Shares23,805,000Free Float7,594,000Market Cap$30.47 million OptionableN/A Beta0.47 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:KLRS) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.